Keyword: Galena BioPharma
Sellas Life Sciences is considering a number of “strategic options” to make sure it can fund development of a pair of cancer vaccines.
The deal gives Sellas a route to public investors as it seeks to guide its WT1-targeting drug through phase 3 trials in AML and mesothelioma.
Galena is engaging in “extensive interactions with numerous companies" seeking “strategic alternatives” that could include a merger, a reverse merger, asset sale, combo and/or a spinoff.
The Securities and Exchange Commission (SEC) has charged 27 companies and individuals over allegations of fraudulent promotion of stocks, as it says it has uncovered a number of writers, sometimes paid by biotech CEOs and comms firms, dressing up unbiased reporting while secretly being paid to tout a company stock.
Galena Biopharma fell more than 80% in premarket trading on news that an Independent Data Monitoring Committee stopped a Phase III trial of its NeuVax in early stage breast cancer for futility.